Evangelia Razis

Dr. Evangelia Razis studied Medicine at Northwestern University, Chicago, IL in a 6 year Honors Program which led to BS in Medical Science followed by an MD in 1987. Subsequently, she completed a 3 year Internal Medicine Residency (Beth Israel Medical Center, New York, NY, 1990), followed by a 3 year Oncology Fellowship (New York Medical College/Westchester County Medical Center, 1993), including a 1 year Bone Marrow Transplantation Fellowship. She then worked as an Instructor of Medicine in New York Medical College from July 1993 to December 1993. Upon returning to Greece she started working as an attending at Hygeia hospital but also completed a Ph.D. in Medicine with honors in July 1998 titled “Phase II, High Dose Chemotherapy with peripheral stem cell support in early high risk breast cancer”, University of Crete, Department of Medicine.
She has a long and continuous commitment to general Medical Oncology with specific interest in Breast Cancer and Neuro-oncology, and actively participates in a number of Medical Associations and cooperative groups focusing on clinical and translational research (ASCO, ESMO, EANO, SNO, HeCOG, National Cancer Institute among others). She is past chair the Educational committee of the European Association of Neurooncology and a member of its executive board.
She is also committed to research and thus is an active member of both the Breast International Group (BIG) and the EORTC Brain Tumor Group and Breast Cancer Group. She was a member of the executive board of BIG.
She has published over 130 papers, has presented several abstracts-posters in international congresses and meetings and has worked on 22 chapters and courses. She has written the international chapter on breast cancer in the ASCO SEP textbook and participates in the ESMO EANO guidelines. She is also in the faculty of ESMO for CNS tumors.
Dr Razis has also invested a significant effort in quality assurance and managed to lead her practice to the first ever Quality certification by ASCO for an international practice in the spring of 2016 and the first ever international certification by ASCO APC4 in 2024. She also chaired the EORTC Brain Tumor Group Quality Assurance Committee and was a member of the ASCO QOPI task force